Lotte S. Fog

Lotte S. Fog

Auto-generated profile, based on publicly available information

Lotte S. Fog

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) Sydney New South Wales Australia

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
CECharlotte Espensen
Charlotte Espensen
AAAne Appelt
Ane Appelt
LFLotte S. Fog
Lotte S. Fog
AGAnita B. Gothelf
Anita B. Gothelf
Juliette THARIATJuliette THARIAT
Juliette THARIAT
JKJens F. Kiilgaard
Jens F. Kiilgaard
Ruthenium-106 (Ru-106) brachytherapy is an established modality for eye-preserving treatment of choroidal melanoma. To achieve optimal treatment outcomes, there should be a balance between tumour control and the risk of healthy tissue toxicity. In this retrospective study, we examined normal tissue complication probability (NTCP) for visual acuity deterioration and late complications to aid the understanding of dose-dependence after Ru-106 treatments. We considered consecutive patients diagnosed with choroidal melanoma and primarily treated at a single institution from 2005–2014. Treatment plans were retrospectively recreated using dedicated software and image guidance to contour the tumour and determine the actual plaque position. Dose distributions were extracted from each plan for all relevant anatomical structures. We considered visual acuity deterioration and late complications (maculopathy, optic neuropathy, ocular hypertension, vascular obliteration, cataract and retinal detachment). Lasso statistics were used to select the most important variables for each analysis. Outcomes were related to dose and clinical characteristics using multivariate Cox regressions analysis. In total, 227 patients were considered and 226 of those were eligible for analysis. Median potential follow-up time was 5.0 years (95% CI: 4.5–6.0). Visual acuity deterioration was related to optic disc-tumour distance and dose metrics from the retina and the macula, with retina V10Gy showing the strongest correlation. Macula V10Gy was the only dose metric impacting risk of maculopathy, while optic disc-tumour distance also proved important. Optic disc V50Gy had the largest impact on optic neuropathy along with optic disc-tumour distance. Optic disc V20Gy was the only variable associated with vascular obliteration. Lens D2% had the largest impact on the risk of cataract along with older age and the largest base dimension. We found no variables associated with the risk of ocular hypertension and retinal detachment. Visual acuity deterioration and most late complications demonstrated dependence on dose delivered to healthy structures in the eye after Ru-106 brachytherapy for choroidal melanomas.

1 June 2019 in Technical Innovations & Patient Support in Radiation Oncology
Verified
Journal Article
Open access
LFLotte S. Fog
Lotte S. Fog
VHVibeke N. Hansen
Vibeke N. Hansen
FKFlemming Kjær-Kristoffersen
Flemming Kjær-Kristoffersen
TBTim Egholm Berlon
Tim Egholm Berlon
PPPeter Meidahl Petersen
Peter Meidahl Petersen
LSLena Specht
Lena Specht
Total body irradiation (TBI) is a part of the conditioning regimen for bone marrow transplant.At the Royal Marsden (Sutton, UK) and Rigshospitalet (Copenhagen, Denmark), we introduced a step and shoot IMRT (SS IMRT) technique for TBI. This technique requires no equipment other than that used to deliver other external beam radiation. In this paper, we describe this technique and report on data from the two clinics. The patients were positioned supine, supported by vacuum bag(s). The entire body of the patients were CT scanned with 5 mm slices. Multiple multi-leaf collimator (MLC) defined fields were used.In-vivo dosimetry was performed at the Royal Marsden for 113 patients.Calculated doses for 18 adult and 4 paediatric patients from Rigshospitalet were extracted. The in-vivo data from the Royal Marsden showed that the mean TLD measured dose difference was -1.9% with a standard deviation of 4.5%.SS IMRT plans for 22 patients from Rigshospitalet resulted in mean doses to the brain, lungs and kidneys all within the range of 11.1-11.8 Gy, while the V(12 Gy) was below 5% for the brain, 2% for the lungs and 0% for the kidneys. SS IMRT is feasible for TBI and can deliver targeted doses to the organs at risk.

1 July 2020 in Physical and Engineering Sciences in Medicine
Verified
Journal Article
Closed access
PDF file
LFLotte S. Fog
Lotte S. Fog
AWAndrew Wirth
Andrew Wirth
MMMichael MacManus
Michael MacManus
SDSimon Downes
Simon Downes
MGMichael Grace
Michael Grace
TKTomas Kron
Tomas Kron

17 October 2023 in Ophthalmology Retina
Verified
Journal Article
Closed access
AHAlison Hiong
Alison Hiong
RORoderick O'Day
Roderick O'Day
LFLotte S. Fog
Lotte S. Fog
DMDaniel McKay
Daniel McKay
JMJohn McKenzie
John McKenzie
MSMark Shackleton
Mark Shackleton

1 December 2008 in Australasian Physics & Engineering Sciences in Medicine
Verified
Journal Article
Closed access
PDF file
LFL. S. Fog
L. S. Fog
PCP. Collins
P. Collins

19 December 2020 in Acta Ophthalmologica
Verified
Journal Article
Closed access
PDF file
CECharlotte A. Espensen
Charlotte A. Espensen
JKJens F. Kiilgaard
Jens F. Kiilgaard
KKKristian Klemp
Kristian Klemp
AGAnita Gothelf
Anita Gothelf
AAAne Appelt
Ane Appelt
LFLotte S. Fog
Lotte S. Fog